Login with email

New to HotPause Health?

Sign up with email

Password Requirements:

  • 8 or more characters
  • 1 uppercase and 1 lowercase letter
  • 1 number
  • 1 of these characters @$!%*?& (no other characters)

Sign up with Google

Reset Password

Enter your email and we will send you a reset link.

Remove Account

Are you sure you want to remove your account?

Deleting your account will not remove the content that you have contributed to HotPause Health.

Log in again to confirm:

Share a Product

Drag image here

or

Links
Product Categories

Share a Doctor

Links
Doctor Categories

Edit Comment

Post a Topic

Categories

    Welcome to HotPause Health!

    We are happy to have you as part of our community.

    Please check your email for a verification link

    *It may take a few minutes for the email to arrive.
    **Be sure to check your spam/junk folder.

    Support the Unboxing Menopause Campaign

    It’s time for the FDA to remove the outdated and misleading boxed warning label on local vaginal estrogen. Let’s Talk Menopause has created a turnkey advocacy campaign to support the “Unboxing Campaign.”

    • 75 million women are in perimenopause, menopause, or postmenopause with 6,000 more reaching menopause each day.
    • Women are not getting the treatment they need or deserve for the extremely common Genitourinary Syndrome of Menopause (GSM).
    • Symptoms of GSM include increased UTIs, urinary incontinence, vaginal dryness, and pain with intercourse. GSM is chronic and “progressive”: it often gets worse as you age and does not go away without treatment.
    • Fortunately, there is a safe and effective treatment: local, vaginal estrogen,, which has been deemed safe and effective in multiple studies and is recommended by top menopause doctors and multiple medical societies.
    • However, women and medical providers are being deterred by an outdated “boxed” warning on local vaginal estrogen products, preventing clinicians from prescribing and women from using. If this boxed warning remains, women will continue to be undertreated for GSM.
    • Removing this label is not just a regulatory change, it’s a critical step toward saving women’s lives and improving their health outcomes by allowing access to safe and effective treatment.
    • Women deserve to have an accurate label on local vaginal estrogen that reflects the most recent evidence-based data.
    • Now is the time for the FDA to distinguish between local estrogen and systemic estrogen products.
    © 2024 HotPause Health, Inc. Privacy Policy Terms of Use Cookie Policy Community Guidelines